🚀 VC round data is live in beta, check it out!
Replek Valuation Multiples
Discover revenue and EBITDA valuation multiples for Replek and similar public comparables like Citius Oncology, Adicet Bio, Cue Biopharma, Valerio Therapeutics and more.
Replek Overview
About Replek
Replek AD is engaged in the development, design and production of generic medicines. The company develops drugs in different pharmaceutical therapeutic categories including anti-platelet, lipid-lowering, atypical antipsychotic, anti-infective, among others. It manufactures drugs in different forms including tablets, capsules, oral solutions, creams and ointments. Its product portfolio consists of Clopidogrel, Atorvastatin, Simvastatin, risperidone, Clarythromycin, Ciprofloxacin, Meloksikam, Risperidon, terazosin, among others. Replek also offers cannabis oil products, food supplements and cosmetics.
Founded
1945
HQ
Employees
408
Website
Sectors
Financials (FY)
EV
$87M
Replek Financials
Replek reported last fiscal year revenue of $37M and EBITDA of $7M.
In the same fiscal year, Replek generated $20M in gross profit, $7M in EBITDA, and $4M in net income.
Replek P&L
In the most recent fiscal year, Replek reported revenue of $37M and EBITDA of $7M.
Replek expects next 12-month revenue of XXX and NTM EBITDA of XXX
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue | — | XXX | $37M | XXX | XXX | XXX |
| Gross Profit | — | XXX | $20M | XXX | XXX | XXX |
| Gross Margin | — | XXX | 53% | XXX | XXX | XXX |
| EBITDA | — | XXX | $7M | XXX | XXX | XXX |
| EBITDA Margin | — | XXX | 20% | XXX | XXX | XXX |
| EBIT Margin | — | XXX | 14% | XXX | XXX | XXX |
| Net Profit | — | XXX | $4M | XXX | XXX | XXX |
| Net Margin | — | XXX | 12% | XXX | XXX | XXX |
| Net Debt | — | — | $6M | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
Replek Stock Performance
Replek has current market cap of $81M, and enterprise value of $87M.
Market Cap Evolution
Replek's stock price is $313.78.
| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $87M | $81M | 0.7% | XXX | XXX | XXX | $16.75 |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free TrialReplek Valuation Multiples
Replek trades at 2.3x EV/Revenue multiple, and 11.7x EV/EBITDA.
Replek Financial Valuation Multiples
As of April 21, 2026, Replek has market cap of $81M and EV of $87M.
Equity research analysts estimate Replek's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Replek has a P/E ratio of 18.7x.
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $81M | XXX | $81M | XXX | XXX | XXX |
| EV (current) | $87M | XXX | $87M | XXX | XXX | XXX |
| EV/Revenue | — | XXX | 2.3x | XXX | XXX | XXX |
| EV/EBITDA | — | XXX | 11.7x | XXX | XXX | XXX |
| EV/EBIT | — | XXX | 16.3x | XXX | XXX | XXX |
| EV/Gross Profit | — | XXX | 4.4x | XXX | XXX | XXX |
| P/E | — | XXX | 18.7x | XXX | XXX | XXX |
| EV/FCF | — | XXX | 23.5x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified Replek Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.
Replek Margins & Growth Rates
Replek's revenue in the last fiscal year grew by 22%.
Replek's revenue per employee in the last FY averaged $0.1M, while opex per employee averaged $0.0M for the same period.
Replek Operational Valuation Multiples
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue Growth | — | XXX | 22% | XXX | XXX | XXX |
| EBITDA Margin | — | XXX | 20% | XXX | XXX | XXX |
| EBITDA Growth | — | XXX | 4% | XXX | XXX | XXX |
| Revenue per Employee | — | XXX | $0.1M | XXX | XXX | XXX |
| Opex per Employee | — | XXX | $0.0M | XXX | XXX | XXX |
| S&M Expenses to Revenue | — | XXX | 3% | XXX | XXX | XXX |
| G&A Expenses to Revenue | — | XXX | 2% | XXX | XXX | XXX |
| Opex to Revenue | — | XXX | 39% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Replek Public Comps
See public comps and valuation multiples for other Biopharmaceuticals comps.
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| LTM | 2026E | 2027E | LTM | 2026E | 2027E | |
| Replek | XXX | XXX | XXX | XXX | XXX | XXX |
| Citius Oncology | XXX | XXX | XXX | XXX | XXX | XXX |
| Adicet Bio | XXX | XXX | XXX | XXX | XXX | XXX |
| Cue Biopharma | XXX | XXX | XXX | XXX | XXX | XXX |
| Valerio Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| Pliant Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Replek M&A Activity
Replek acquired XXX companies to date.
Last acquisition by Replek was on XXXXXXXX, XXXXX. Replek acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Acquisitions by Replek
| Acquired Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Get Verified M&A Valuation Multiples
Sign up to see revenue and EBITDA valuation multiples for 150K+ M&A deals.
Start Free TrialReplek Investment Activity
Replek invested in XXX companies to date.
Replek made its latest investment on XXXXXXXX, XXXXX. Replek invested in XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Investments by Replek
| Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout Replek
| When was Replek founded? | Replek was founded in 1945. |
| Where is Replek headquartered? | Replek is headquartered in North Macedonia. |
| How many employees does Replek have? | As of today, Replek has over 408 employees. |
| Is Replek publicly listed? | Yes, Replek is a public company listed on Macedonian Stock Exchange. |
| What is the stock symbol of Replek? | Replek trades under REPL ticker. |
| Who are competitors of Replek? | Replek main competitors are Citius Oncology, Adicet Bio, Cue Biopharma, Valerio Therapeutics. |
| What is the current market cap of Replek? | Replek's current market cap is $81M. |
| What is the current revenue of Replek? | Replek's last fiscal year revenue is $37M. |
| What is the current EV/Revenue multiple of Replek? | Current revenue multiple of Replek is 2.3x. |
| Is Replek profitable? | No, Replek is not profitable. |
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.